Nanoscope Therapeutics to Present Long-Term Vision Restoration Data at Eyecelerator and ARVO 2025
Nanoscope Therapeutics will showcase 126-week results from its MCO-010 optogenetic therapy for retinitis pigmentosa (RP) at the 2025 Eyecelerator and ARVO annual meetings. MCO-010 is the first one-time intravitreal gene therapy shown to restore vision in advanced RP patients. The company is preparing for commercialization and a Biologics License Application (BLA) submission.
Nanoscope Therapeutics to Present Long-Term Vision Restoration Data at Eyecelerator and ARVO 2025